Airplanes are loud and may damage your hearing. Here's what helps.
Despite advances in acoustic sound management, experts say this constant noise could be a source of discomfort and potentially even a risk to health and hearing. However, there is not much direct research on how airplane noise affects passengers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Swiss exoplanet pioneer reflects on Earth's place in the cosmos
In October 1995, Michel Mayor and Didier Queloz made a groundbreaking discovery: the first exoplanet orbiting a solar-type star. This moment marked the beginning of a new era in astronomy and planetary science, earning the Swiss pair the 2019 Nobel Prize in Physics. In a recent visit to the Sorbonne, Queloz shared some of his insights with Radio France Internationale. Since the first discovery, nearly 6,000 exoplanets have been confirmed, with thousands more candidates awaiting verification. Each one offers a small glimpse into the diversity of planetary systems across the galaxy. While both Mayor and Queloz are Swiss, they come from the French-speaking region of Switzerland and have long-standing academic ties to French institutions. Growing interest in exoplanets Their discovery reverberated strongly through the French scientific community, contributing to a surge of interest in exoplanetology in France. Professor Queloz, for example, has collaborated with Paris Sciences et Lettres University and recently delivered a public lecture at Sorbonne University. During his visit to Paris, Queloz explained: 'Looking for exoplanets is essentially looking for us.' His words capture the deeper motivation behind this cosmic quest - not merely cataloging distant worlds, but seeking to understand our own place in the universe. From the Lab: French researchers uncover why solar system planets are unlikely to collide Philosphy and science Read more on RFI EnglishRead also:From the Lab: French researchers uncover why solar system planets are unlikely to collideFrom The Lab: How researchers reconstructed the face of a Napoleonic soldierFrom The Lab: France's SOLEIL synchrotron shines light on secrets of matter
Yahoo
26 minutes ago
- Yahoo
SpaceX launches mystery satellite to geostationary transfer orbit (video)
When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX launched a mystery satellite to geostationary transfer orbit (GTO) from Florida's Space Coast early Sunday morning (July 13). A Falcon 9 rocket lifted off from Cape Canaveral Space Force Station Sunday at 1:04 a.m. EDT (0504 GMT), on a mission SpaceX called Commercial GTO-1. The company didn't identify the payload, though it's believed to be an Israeli communications satellite called Dror-1 . "Dror-1 is a geostationary communication satellite built and developed by Israel Aerospace Industries (IAI)," wrote. "It is intended to meet the satellite communication needs of Israel for the next 15 years," the outlet added. "Dror-1 is comprised primarily of local Israeli technologies developed at IAI, including an advanced digital communication payload and 'smartphone in space' capabilities, to provide communication agility throughout the satellite's lifetime in space." Geostationary orbit lies 22,236 miles (35,786 kilometers) above Earth. At this altitude, orbital speed matches our planet's rotational speed, so spacecraft in this path "hover" over the same patch of Earth continuously. Booster 1083 missions Crew-8 | Polaris Dawn | CRS-31 | Astranis: From One to Many | IM-2 | 7 Starlink missions The Falcon 9's first stage, designated B1083, came back to Earth as planned on Sunday. It touched down about 8.5 minutes after liftoff on the SpaceX drone ship "Just Read the Instructions," which was stationed in the Atlantic Ocean. It was the 13th launch and landing for this particular booster, according to a SpaceX mission description. That description did not give an estimated time for the deployment of the Commercial GTO-1 satellite.
Yahoo
27 minutes ago
- Yahoo
Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series
WATERTOWN, Mass., July 15, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird's Biotech Discovery Series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at A replay of the webcast will be available following the event and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
